DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 9.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $262,285 | +131042.5% | 8,888 | +1.9% | 0.00% | 0.0% |
Q1 2023 | $200 | -26.7% | 8,724 | -11.5% | 0.00% | 0.0% |
Q4 2022 | $273 | -99.9% | 9,858 | -16.7% | 0.00% | -50.0% |
Q3 2022 | $362,000 | +9.7% | 11,834 | +5.4% | 0.00% | 0.0% |
Q2 2022 | $330,000 | -47.7% | 11,230 | -42.9% | 0.00% | -33.3% |
Q1 2022 | $631,000 | -13.9% | 19,652 | +19.4% | 0.00% | 0.0% |
Q4 2021 | $733,000 | -1.6% | 16,458 | +11.2% | 0.00% | -25.0% |
Q3 2021 | $745,000 | +32.1% | 14,799 | +105.3% | 0.00% | +33.3% |
Q2 2021 | $564,000 | +126.5% | 7,207 | +64.2% | 0.00% | +50.0% |
Q1 2021 | $249,000 | +19.1% | 4,390 | +75.6% | 0.00% | 0.0% |
Q4 2020 | $209,000 | +134.8% | 2,500 | 0.0% | 0.00% | +100.0% |
Q3 2020 | $89,000 | – | 2,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |